Trials / Terminated
TerminatedNCT01814722
Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)
Quality of Life of HIV-infected Patients Switched to Raltegravir Versus Other Antiretroviral Regimens
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 63 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center, longitudinal observational study of adult human immunodeficiency virus (HIV) participants at academic and community-based practices in the United States who are switching from first-line to second-line therapy. The study's primary hypothesis is that HIV participants switching to raltegravir-based regimens will have better Medical Outcomes Study-HIV (MOS-HIV) Health Survey scores than participants switched to non-nucleoside reverse transcriptase inhibitor (NNRTI)-based or protease inhibitor (PI)-based regimens.
Conditions
Timeline
- Start date
- 2012-11-09
- Primary completion
- 2013-10-31
- Completion
- 2013-10-31
- First posted
- 2013-03-20
- Last updated
- 2017-04-21
- Results posted
- 2014-10-09
Source: ClinicalTrials.gov record NCT01814722. Inclusion in this directory is not an endorsement.